We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
InMode (INMD) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest market close, InMode (INMD - Free Report) reached $21.01, with a +0.05% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.34% for the day. At the same time, the Dow added 0.03%, and the tech-heavy Nasdaq lost 0.56%.
The maker of cosmetic surgery devices's stock has dropped by 1.22% in the past month, falling short of the Medical sector's gain of 5.72% and the S&P 500's gain of 2.56%.
Investors will be eagerly watching for the performance of InMode in its upcoming earnings disclosure. The company is expected to report EPS of $0.62, down 20.51% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $125.5 million, showing a 6.04% drop compared to the year-ago quarter.
It is also important to note the recent changes to analyst estimates for InMode. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 7.94% decrease. As of now, InMode holds a Zacks Rank of #4 (Sell).
Digging into valuation, InMode currently has a Forward P/E ratio of 7.95. This signifies a discount in comparison to the average Forward P/E of 21.1 for its industry.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 185, putting it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
InMode (INMD) Advances While Market Declines: Some Information for Investors
In the latest market close, InMode (INMD - Free Report) reached $21.01, with a +0.05% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 0.34% for the day. At the same time, the Dow added 0.03%, and the tech-heavy Nasdaq lost 0.56%.
The maker of cosmetic surgery devices's stock has dropped by 1.22% in the past month, falling short of the Medical sector's gain of 5.72% and the S&P 500's gain of 2.56%.
Investors will be eagerly watching for the performance of InMode in its upcoming earnings disclosure. The company is expected to report EPS of $0.62, down 20.51% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $125.5 million, showing a 6.04% drop compared to the year-ago quarter.
It is also important to note the recent changes to analyst estimates for InMode. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 7.94% decrease. As of now, InMode holds a Zacks Rank of #4 (Sell).
Digging into valuation, InMode currently has a Forward P/E ratio of 7.95. This signifies a discount in comparison to the average Forward P/E of 21.1 for its industry.
The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 185, putting it in the bottom 27% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.